BioNTech Halts Colorectal Cancer Vaccine Trial

Multiple independent outlets confirm the core event: BioNTech announced on Friday, August 28, 2026, that it would discontinue its Phase 2 BNT122-01 trial of autogene cevumeran as a monotherapy in high-risk colorectal cancer patients who had undergone surgery. BioSpace reported that an Independent Data Safety Monitoring Board (DSMB) recommended the discontinuation, citing a numerical imbalance in overall survival between treatment arms and concluding that further continuation was unlikely to change the efficacy outcome. WirtschaftsWoche and Apotheke Adhoc corroborated the same details, including the DSMB's prior October 2025 assessment that the data were not yet mature enough to draw reliable conclusions.

The framing in the original post as a "safety review" is partially misleading. The trial was halted for futility — the study was not showing evidence that the vaccine worked as a standalone treatment — not because regulators or the company identified a specific safety hazard. The survival imbalance was a contributing factor in the DSMB's recommendation, but the primary rationale was that the trial would not meet its efficacy endpoint. BioNTech's own press release, as quoted by WirtschaftsWoche, stated that further continuation would not change the efficacy signal.

The claim that BioNTech "did not respond to a request for comment" could not be independently verified from the provided sources, though BioSpace's reporting indicates the company issued a public press release on the matter. The poster's added commentary — "Since when does something like that bother people again? The EMA would surely have approved it" — is rhetorical opinion rather than a factual assertion, and reflects skepticism about regulatory standards rather than a verifiable claim about the EMA's actual review process.

Context matters here: the same week brought positive news for a competing mRNA cancer vaccine. Moderna and Merck reported that their Phase 3 trial of intismeran autogene combined with Keytruda met its primary endpoint in melanoma, sending Moderna's stock up sharply. BioNTech's separate pancreatic cancer trial of autogene cevumeran, which combines the vaccine with Roche's Tecentriq and chemotherapy, is continuing. The colorectal cancer setback is therefore a specific program failure, not a broader collapse of BioNTech's oncology pipeline or mRNA cancer vaccine research.